PMID- 23743928
OWN - NLM
STAT- MEDLINE
DCOM- 20140811
LR  - 20230210
IS  - 1530-0285 (Electronic)
IS  - 0893-3952 (Linking)
VI  - 26
IP  - 12
DP  - 2013 Dec
TI  - Testing for ALK rearrangement in lung adenocarcinoma: a multicenter comparison of 
      immunohistochemistry and fluorescent in situ hybridization.
PG  - 1545-53
LID - 10.1038/modpathol.2013.87 [doi]
AB  - Rearrangements of anaplastic lymphoma kinase (ALK) gene in non-small cell lung 
      cancer (NSCLC) define a molecular subgroup of tumors characterized clinically by 
      sensitivity to ALK tyrosine kinase inhibitors such as crizotinib. Although ALK 
      rearrangements may be detected by reverse transcriptase-PCR, immunohistochemistry 
      or fluorescence in situ hybridization (FISH), the optimal clinical strategy for 
      identifying ALK rearrangements in clinical samples remains to be determined. We 
      evaluated immunohistochemistry using three different antibodies (ALK1, 5A4 and 
      D5F3 clones) to detect ALK rearrangements and compared those with FISH. We report 
      the frequency and clinicopathologic features of lung cancers harboring ALK 
      translocations in 594 resected NSCLCs (470 adenocarcinomas; 83 squamous 
      carcinomas, 26 large cell carcinomas and 15 other histological subtypes) using a 
      tissue microarray approach. We identified an ALK gene rearrangement in 7/594 
      cases (1%) by FISH and all anti-ALK antibodies correctly identified the seven 
      ALK-positive cases (100% sensitivity), although the intensity of staining was 
      weak in some cases. These data indicate that the use of antibodies with high 
      sensitivity and avidity to ALK may provide an effective pre-screening technique 
      to complement the more expensive and labor-intensive approach of ALK FISH 
      testing.
FAU - Selinger, Christina I
AU  - Selinger CI
AD  - Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred 
      Hospital, Camperdown, NSW, Australia.
FAU - Rogers, Toni-Maree
AU  - Rogers TM
FAU - Russell, Prudence A
AU  - Russell PA
FAU - O'Toole, Sandra
AU  - O'Toole S
FAU - Yip, Poyee
AU  - Yip P
FAU - Wright, Gavin M
AU  - Wright GM
FAU - Wainer, Zoe
AU  - Wainer Z
FAU - Horvath, Lisa G
AU  - Horvath LG
FAU - Boyer, Michael
AU  - Boyer M
FAU - McCaughan, Brian
AU  - McCaughan B
FAU - Kohonen-Corish, Maija Rj
AU  - Kohonen-Corish MR
FAU - Fox, Stephen
AU  - Fox S
FAU - Cooper, Wendy A
AU  - Cooper WA
FAU - Solomon, Benjamin
AU  - Solomon B
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20130607
PL  - United States
TA  - Mod Pathol
JT  - Modern pathology : an official journal of the United States and Canadian Academy 
      of Pathology, Inc
JID - 8806605
RN  - EC 2.7.10.1 (ALK protein, human)
RN  - EC 2.7.10.1 (Anaplastic Lymphoma Kinase)
RN  - EC 2.7.10.1 (Receptor Protein-Tyrosine Kinases)
SB  - IM
CIN - Mod Pathol. 2014 Oct;27(10):1423-4. PMID: 25269809
CIN - Mod Pathol. 2014 Oct;27(10):1424-5. PMID: 25269810
MH  - Adenocarcinoma/*genetics
MH  - Adenocarcinoma of Lung
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Anaplastic Lymphoma Kinase
MH  - Female
MH  - Gene Rearrangement
MH  - Humans
MH  - Immunohistochemistry/*methods
MH  - In Situ Hybridization, Fluorescence/*methods
MH  - Lung Neoplasms/*genetics
MH  - Male
MH  - Middle Aged
MH  - Receptor Protein-Tyrosine Kinases/*genetics
MH  - Tissue Array Analysis
EDAT- 2013/06/08 06:00
MHDA- 2014/08/12 06:00
CRDT- 2013/06/08 06:00
PHST- 2013/01/21 00:00 [received]
PHST- 2013/03/03 00:00 [revised]
PHST- 2013/03/23 00:00 [accepted]
PHST- 2013/06/08 06:00 [entrez]
PHST- 2013/06/08 06:00 [pubmed]
PHST- 2014/08/12 06:00 [medline]
AID - S0893-3952(22)03003-4 [pii]
AID - 10.1038/modpathol.2013.87 [doi]
PST - ppublish
SO  - Mod Pathol. 2013 Dec;26(12):1545-53. doi: 10.1038/modpathol.2013.87. Epub 2013 
      Jun 7.